Introduction
iRhythm Technologies is a San Francisco-based medical device company founded in 2006 that provides digital healthcare solutions for cardiac arrhythmia detection and management. Quentin Blackford serves as President and Chief Executive Officer — a role confirmed on iRhythm’s investor relations governance pages and in the company’s third-quarter 2025 financial results release reviewed in July 2026. Co-founders Uday N. Kumar, MD, and Bill Moore established iRhythm to address limitations of short-duration Holter monitoring through the Zio wearable patch and cloud-based analytics platform.
iRhythm is publicly traded on NASDAQ (IRTC) and describes its mission as transforming cardiac care through actionable insights derived from wearable biosensors and proprietary algorithms applied to millions of heartbeats.
What the company does
iRhythm manufactures and services the Zio portfolio of ambulatory electrocardiogram monitoring solutions, including extended-wear patch monitors, mobile cardiac telemetry (Zio AT), and related cloud analytics that distill continuous ECG data into clinician-ready reports. The company combines device logistics, AI-assisted arrhythmia detection, and operational services that health systems integrate into cardiology and primary care pathways for atrial fibrillation and broader arrhythmia management.
In 2025 iRhythm expanded its AI strategy through a strategic partnership with Lucem Health, applying predictive AI to identify patients at elevated arrhythmia risk — including those with comorbid conditions such as diabetes and chronic kidney disease — before traditional symptomatic referral pathways trigger monitoring orders. Blackford framed this partnership in Q2 and Q3 2025 releases as a step toward predictive, preventive cardiac care powered by AI and informed by population-scale data.
iRhythm’s service model bundles device fulfillment, patient compliance support, and algorithm-assisted report generation — a full-stack approach that distinguishes it from pure software vendors selling arrhythmia classifiers without operational infrastructure.
Who it serves
iRhythm serves cardiologists, electrophysiology practices, primary care networks, and health systems managing large at-risk populations. The company reports deployments across major U.S. health systems, value-based care organizations, and international markets including Japan commercial launch referenced in 2025 releases. Payers and employers encounter iRhythm indirectly through health-system contracts where earlier arrhythmia detection supports stroke prevention and downstream cost avoidance.
Population health teams use iRhythm in proactive screening programs where AI risk stratification from partners like Lucem Health helps prioritize which patients receive Zio monitoring — a workflow shift from reactive symptom-driven ordering.
Company background
Kumar and Moore founded iRhythm in 2006 in San Francisco, drawing on Stanford Biodesign-era clinical insight into intermittent arrhythmia detection gaps. The company received FDA clearance for the Zio Patch, completed a 2016 NASDAQ initial public offering, and expanded internationally while navigating Medicare reimbursement dynamics that materially affected revenue in prior years. Blackford joined as CEO in October 2021 from Dexcom, bringing operational scaling experience from continuous glucose monitoring — a parallel wearable-data business model.
Under Blackford’s tenure iRhythm surpassed ten million cumulative patient reports posted, expanded Zio AT penetration in major health systems, and pursued next-generation products including Zio MCT FDA submission and early sleep diagnostics work referenced in 2025 investor communications.
Product and AI capabilities
iRhythm applies machine learning to ambulatory ECG signals for arrhythmia detection, burden quantification, and report prioritization — capabilities embedded in its ZEUS system and broader Zio analytics stack rather than sold as standalone AI modules. The Lucem Health partnership adds upstream predictive risk stratification using patient populations with comorbid chronic disease, enabling health systems to select monitoring candidates before clinical events escalate.
Blackford’s Q3 2025 commentary emphasized EHR integration progress, primary care expansion, and clinical evidence accumulation alongside AI partnerships — positioning iRhythm as a platform spanning device, service, and predictive analytics rather than a single-algorithm vendor.
Key developments
2006: iRhythm founded in San Francisco. October 2021: Quentin Blackford appointed President and CEO (IR press release). 2025: Strategic Lucem Health AI partnership announced; Q3 2025 revenue up 30.7% year-over-year with record free cash flow per official IR release cited in this profile.
Why it matters
iRhythm matters because ambulatory cardiac monitoring is a mature, reimbursed category where AI differentiation increasingly appears in patient selection and population-health integration — not only post-capture arrhythmia classification. The Lucem partnership is a concrete 2025 milestone showing medical-device incumbents acquiring predictive AI capabilities rather than building all models in-house. iRhythm also sits in Brel’s medical devices coverage distinct from consumer wearables or hospital ECG AI point solutions where regulatory and buyer pathways differ.
Health-system cardiology leaders evaluating iRhythm should assess EHR write-back depth and value-based care contract alignment alongside algorithm performance — deployment economics often determine adoption more than sensitivity metrics alone.
Sector context
iRhythm belongs in Brel’s AI in healthcare coverage under medical devices and cardiac monitoring, related to digital health remote monitoring vendors such as Biofourmis but focused on arrhythmia-specific ambulatory ECG rather than multi-vital RPM platforms. Readers should separate FDA device clearances from AI partnership announcements — predictive risk tools may follow different regulatory paths than Zio monitoring itself.
Sources and references
iRhythm Q3 2025 financial results release and Board of Directors governance page.
- iRhythm — Q3 2025 financial results (investors.irhythmtech.com)
- iRhythm — Board of Directors (investors.irhythmtech.com)
Reviewed July 10, 2026. Quentin Blackford is CEO. sec.gov removed as supporting source per batch 3 rules.